1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).
This solicitation invites eligible United States small business concerns to submit SBIR applications for research and development that has a strong potential for commercialization and aligns with the missions of NIH, CDC, and FDA to improve health and save lives. The program supports the development of promising technologies and products in the life sciences.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs) that are US-owned and operated. Small businesses must have no more than 500 employees, majority ownership by U.S. Citizens or another U.S.-based small business, and all work performed in the U.S. Confirm the full requirements in the official notice before applying.
The current listing shows generally up to $600K for Phase I and $3.5M for Phase II awards. Specific grant amounts vary. Verify award ceilings, matching requirements, and allowable costs in the official notice.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read articleCDC-RFA-EH-27-0074 posted as a forecast September 22, 2026: 6 expected awards at $750,000 to $900,000. That is flat funding against the expiring cycle — and the only proven way in is the consortium model Arizona used to bring three states under one award.
Read article